⚕ GalenOps field
←

SITE013-0356

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-04-21

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 25); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-27 (study day 84); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 88); relationship: Y

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-07 (study day 95); relationship: N

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-10-31 (study day 180); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-09 (study day 189); relationship: N

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-10 (study day 190); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-16 (study day 257); relationship: not assessed

Data queries

No data queries.